Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIGN: Fostamatinib in IgA Nephropathy
NCT02112838Phase 2Completed
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Oct 2014
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of fostamatinib in IgA nephropathy (IgAN), sponsored by Rigel Pharmaceuticals, Inc.. Started Oct 2014; status: completed.
02
Drugs
fostamatinib
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT02112838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02112838.